REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced that data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be presented at the SSIEM 2024 Annual Symposium in Porto, Portugal from September 3-6, 2024. The presentation, titled 'CAMPSIITE™ phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II),' will be given by Dr. Roberto Giugliani on Wednesday, September 4, 2024, at 6:15 p.m. WEST. This presentation suggests ongoing progress in REGENXBIO's gene therapy research for MPS II.

Positive

• Presentation of clinical data for RGX-121 program at a major symposium
• Ongoing development of gene therapy for MPS II (Hunter syndrome)

Negative

• None.

ROCKVILLE, Md., Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking place in Porto, Portugal from September 3-6, 2024.

Abstract Title: CAMPSIITE™ phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II) (PO-205)
Presenter: Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil
Date/Time: Wednesday, September 4, 2024; 6:15 p.m. WEST (Western European Summer Time)

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA^® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-2024-annual-symposium-302231163.html

SOURCE REGENXBIO Inc.

FAQ

What is REGENXBIO presenting at the SSIEM 2024 Annual Symposium?

REGENXBIO is presenting data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, at the SSIEM 2024 Annual Symposium.

When and where is the SSIEM 2024 Annual Symposium taking place?

The SSIEM 2024 Annual Symposium is taking place in Porto, Portugal from September 3-6, 2024.

Who is presenting the RGX-121 data for REGENXBIO (RGNX) at the symposium?

Dr. Roberto Giugliani, Professor at the Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil, is presenting the RGX-121 data for REGENXBIO.

What is the title of REGENXBIO's (RGNX) presentation at the SSIEM 2024 symposium?

The presentation title is 'CAMPSIITE™ phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II)'.